Prescription medicine
Berdazimer Brand names: Zelsuvmi
Berdazimer (Zelsuvmi) is a prescription medicine with an FDA approval on record since 2024. No generic is listed; pharmacies paid $61.89 per gram (Zelsuvmi 10.3% gel) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the berdazimer FDA label on DailyMed (effective July 8, 2025, LNHC, Inc.); the NDA 217424 record on Drugs@FDA; every berdazimer label on DailyMed.
Highlights of the record
FDA label of July 8, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageZELSUVMI™ is indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older.
Forms and strengths
Kit.
On the market
- Earliest approval on file
- January 5, 2024 Zelsuvmi, Lnhc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- July 10, 2035 Zelsuvmi gel; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $61.89 per gram Zelsuvmi 10.3% gel
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 71 through July 30, 2026
What is berdazimer used for?
From the label: indications and usageZELSUVMI™ is indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older. ZELSUVMI™ is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older.
Source: FDA drug label (ZELSUVMI), LNHC, Inc., effective July 8, 2025 (SPL set 76b17622-bdb9-41ea-b962-c2acc0df71f7), via openFDA; the full label on DailyMed
Is there a generic for berdazimer (Zelsuvmi)?
No generic berdazimer is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 14 patents for Zelsuvmi gel: the compound patent runs to May 30, 2026, and the last listed entry to July 10, 2035. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2024 earliest approval on file
- 2035 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for berdazimer (Zelsuvmi)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $61.89 per gram (Zelsuvmi 10.3% gel). The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Zelsuvmi 10.3% gel (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Zelsuvmi 10.3% gel | Brand | $61.89 per gram | n/a | n/a |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for berdazimer?
The FDA Adverse Event Reporting System holds 71 reports that list berdazimer among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 0 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Berdazimer side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other